Navigation Links
Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
Date:4/24/2013

HERSHEY, Pa. and ROCKVILLE, Md., April 24, 2013 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Hershey, PA), a leading developer of novel allergy immunotherapies, announced the preliminary results of a Phase I Study to treat individuals with an allergy to Japanese red cedar ("JRC").  The Company is pleased to report that the immunotherapeutic vaccine, JRC-LAMP-vax™, appears to have met all of its primary safety end points.  In addition, preliminary allergic marker results indicate a favorable trend in resolving the allergy.

Within the three subject sub-groups, (24 total patients) there were no reports of any Severe Adverse Events (SAE).  A small number of mild adverse events were reported in about 10% of the vaccinations, generally related to soreness associated with the intra-muscular injection.  The safety results are consistent with other clinical studies that have incorporated LAMP, which also showed the vaccine to be safe and well tolerated.  In addition to monitoring vaccine safety, subjects were also evaluated for immunological markers of allergy including circulating IgE, immunoglobulin G (IgG) and skin test reactivity. 

At the 2013 BIO International Convention, the CEO of Immunomic Therapeutics, Dr. William Hearl , presented the preliminary data for cedar specific IgE and for skin test reactivity.  All patients had stable IgE levels including those patients who entered the study as non-allergic to JRC.  This observation indicates that the vaccine does not induce a new IgE antibody response in either naive or allergic subjects.

Skin testing is perhaps the oldest and most reliable form of allergy testing.  Skin testing has been performed for 100 years and continues to be the test of choice for the diagnosis of allergic disease.  A number of the subjects, both skin test positive and skin test negative at the start of the trial, were found to be skin test negative at the end of the study: 5 of 6 converted from positive to negative for whole JRC extract and all subjects were negative for the specific cedar allergen Cry J2.  In addition, all skin test negative subjects (5) remained skin test negative at the end of the Phase I study.

"Immunomic Therapeutics, Inc., is proud to present these promising results for our first in human Phase I study.  While we are quite excited about the initial skin test results it is important to note that this is a very small number of subjects and we have no indication that the treatment would alleviate the subjects' rhinitis upon exposure to cedar pollen.  Nevertheless, the skin test results are extraordinary in that reversal of a positive result within 132 days of treatment is not usually observed with traditional immunotherapy which may last years and require a 100 or more shots.  To have seen that result within the course of this study gives us – and everyone with an allergy – hope that a solution may be on the horizon."

The Company is planning to continue collecting data for about the next 30 days and will have a more complete report available later this year.  ITI is also planning on initiating a Phase II study of JRC-LAMP-vax later this year and following that in 2014 with our first food allergy immunotherapy for peanut allergy, ARA-LAMP-vax. 

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company with lab facilities in Rockville, MD and process-development plant in Hershey, PA.  ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases.  For more information about ITI and LAMP Technology please visit www.immunomix.com

CONTACT:

Dr. Bill Hearl, President / CEO

Phone:  1-717-327-1919

Immunomix@gmail.com          

Immunomic Therapeutics, Inc.

1214 Research Blvd, Suite 201

Hershey, PA 17036

E-mail:  info@immunomix.com

Web: www.immunomix.com


'/>"/>
SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):